Pre-made Tafasitamab benchmark antibody ( Whole mAb, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-543

Pre-Made Tafasitamab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-543-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Tafasitamab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
INN Name Tafasitamab
TargetCD19
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesMorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor
Conditions ApprovedDiffuse large B cell lymphoma
Conditions ActiveChronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Follicular lymphoma;Marginal zone B-cell lymphoma
Conditions Discontinuedna
Development TechMorphoSys HuCAL Phage Display;XmAb Engineering Technology